KR100449677B1 - Il-6 활성 저해 물질 - Google Patents
Il-6 활성 저해 물질 Download PDFInfo
- Publication number
- KR100449677B1 KR100449677B1 KR1019970708022A KR19970708022A KR100449677B1 KR 100449677 B1 KR100449677 B1 KR 100449677B1 KR 1019970708022 A KR1019970708022 A KR 1019970708022A KR 19970708022 A KR19970708022 A KR 19970708022A KR 100449677 B1 KR100449677 B1 KR 100449677B1
- Authority
- KR
- South Korea
- Prior art keywords
- plasmid
- sequence
- nucleotide sequence
- activity
- apre
- Prior art date
Links
- 102000004889 Interleukin-6 Human genes 0.000 title claims abstract description 89
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 89
- 230000000694 effects Effects 0.000 title claims abstract description 34
- 239000003112 inhibitor Substances 0.000 title description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 47
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 27
- 239000002773 nucleotide Substances 0.000 claims abstract description 26
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 26
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 14
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 14
- 230000027455 binding Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 135
- 210000004027 cell Anatomy 0.000 description 69
- 108700008625 Reporter Genes Proteins 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 35
- 108060001084 Luciferase Proteins 0.000 description 33
- 238000012360 testing method Methods 0.000 description 32
- 239000012634 fragment Substances 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 25
- 238000001890 transfection Methods 0.000 description 25
- 239000005089 Luciferase Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 10
- 238000000246 agarose gel electrophoresis Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000003571 reporter gene assay Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 101000826373 Homo sapiens Signal transducer and activator of transcription 3 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 238000012761 co-transfection Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108050005077 Haptoglobin Proteins 0.000 description 3
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000006580 General Transcription Factors Human genes 0.000 description 1
- 108010008945 General Transcription Factors Proteins 0.000 description 1
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 1
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000050796 human HP Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (11)
- IL-6 활성을 저해할 수 있는 뉴클레오티드 서열에 있어서,서열은 i)APRE 부분과 ii) 전사 인자 결합 부분으로 구성되며,이때, APRE 요소는 서열 ZXMYKGKAA로 구성되며,여기서, Z는 T 또는 G를 나타내거나 또는 없을 수 있고;X는 T 또는 없을 수 있고;M은 C 또는 A이고; Y는 C 또는 T이고;K는 T 또는 G이 되는 것을 특징으로 하는 IL-6 활성을 저해할 수 있는 뉴클레오티드 서열.
- 제 1 항에 있어서, 서열 (i)은 TTCTGGGAA인 것을 특징으로 하는 뉴클레오티드 서열.
- 제 1 항에 있어서, APRE 요소(i)는 적어도 2회 반복되는 것을 특징으로 하는 뉴클레오티드 서열.
- 제 3 항에 있어서, APRE 요소는 3 내지 10회 반복되는 것을 특징으로 하는 뉴클레오티드 서열.
- 제 4 항에 있어서, APRE 요소는 8회 반복되는 것을 특징으로 하는 뉴클레오티드 서열.
- 제 1 항에 있어서, 서열 (i)은 적어도 두 개의 상이한 APRE 요소로 구성되는 것을 특징으로 하는 뉴클레오티드 서열.
- 제 1 항에 있어서, 서열 (ii)은 전사 인자 결합부위를 구성하는 올리고뉴클레오티드 서열로 SV40 초기 프로모터로 구성되는 것을 특징으로 하는 뉴클레오티드 서열.
- 제 1 항에 있어서, SEQ ID NO:1에 제시된 서열인 것을 특징으로 하는 뉴클레오티드 서열.
- 제 1 항 내지 제8항중 어느 한 항에 따른 뉴클레오티드 서열을 포함하는 플라스미드 벡터에 있어서, 벡터는 pM8SV이고 이의 제한효소 지도는 도 1에 제시된 것과 같은 것을 특징으로 하는 플라스미드 벡터.
- IL-6 활성을 저해 조절하여, 류마티스 관절염, 사구체신염, 건선 및 자가면역 질환을 경감시킬 수 있는 약학조성물에 있어서, 활성성분으로 제 1 항 내지 제8항중 어느 한 항에 따른 뉴클레오티드 서열을 포함하고, 하나이상의 제약학적 수용가능한 담체 또는 부형제로 구성되고, 활성 성분은 IL-6 활성을 방해하는 것을 특징으로 하는 류마티스 관절염, 사구체신염, 건선 및 자가면역 질환을 경감시킬 수 있는 약학 조성물.
- IL-6 활성을 저해 조절하여, 류마티스 관절염, 사구체신염, 건선 및 자가면역 질환을 경감시킬 수 있는 약학조성물에 있어서, 활성성분으로 제 9 항에 따른 플라스미드 벡터를 포함하고, 하나이상의 제약학적 수용가능한 담체 또는 부형제로 구성되고, 활성 성분은 IL-6 활성을 방해하는 것을 특징으로 하는 류마티스 관절염, 사구체신염, 건선 및 자가면역 질환을 경감시킬 수 있는 약학 조성물.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1995/001778 WO1996035782A1 (en) | 1995-05-11 | 1995-05-11 | Il-6 activity inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
KR19990014681A KR19990014681A (ko) | 1999-02-25 |
KR100449677B1 true KR100449677B1 (ko) | 2004-11-20 |
Family
ID=8166014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970708022A KR100449677B1 (ko) | 1995-05-11 | 1995-05-11 | Il-6 활성 저해 물질 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6004813A (ko) |
EP (1) | EP0824588B1 (ko) |
JP (1) | JP4173539B2 (ko) |
KR (1) | KR100449677B1 (ko) |
AT (1) | ATE271128T1 (ko) |
AU (1) | AU715125B2 (ko) |
CA (1) | CA2220433C (ko) |
DE (1) | DE69533264T2 (ko) |
DK (1) | DK0824588T3 (ko) |
ES (1) | ES2220929T3 (ko) |
HK (1) | HK1016213A1 (ko) |
IL (1) | IL118158A (ko) |
MX (1) | MX9708663A (ko) |
RU (1) | RU2205874C2 (ko) |
UA (1) | UA63888C2 (ko) |
WO (1) | WO1996035782A1 (ko) |
ZA (1) | ZA963593B (ko) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
CA2237114A1 (en) * | 1995-11-07 | 1997-05-15 | Kaneka Corporation | Autoantigens |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
EP0972780A1 (en) * | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
JP4748338B2 (ja) | 1998-09-11 | 2011-08-17 | 味の素株式会社 | ベンゼン誘導体及びその医薬用途 |
AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
AU2003216585A1 (en) * | 2002-04-10 | 2003-10-20 | Orchid Chemicals And Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
US8263746B2 (en) * | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
KR20080025662A (ko) * | 2005-03-18 | 2008-03-21 | 오키드 케미칼즈 앤드 파마수티컬즈 리미티드 | 신규 티로신 유도체 |
WO2006126074A2 (en) * | 2005-05-26 | 2006-11-30 | Orchid Research Laboratories Limited | Heterocyclic derivatives |
US20090163521A1 (en) * | 2005-06-28 | 2009-06-25 | Orchid Research Laboratories Limited | Novel Pyrazolopyrimidinone Derivatives |
CN103554259B (zh) | 2005-10-12 | 2016-05-18 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
JP5237115B2 (ja) * | 2006-01-19 | 2013-07-17 | オーキッド リサーチ ラボラトリーズ リミテッド | 新規複素環類 |
US7863446B2 (en) * | 2006-01-19 | 2011-01-04 | Orchid Research Laboratories Limited | Heterocycles |
US20080221103A1 (en) * | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
AU2008251320B2 (en) | 2007-05-11 | 2013-12-19 | Adynxx, Inc. | Gene expression and pain |
BRPI0912029A2 (pt) | 2008-02-01 | 2020-06-30 | Orchid Research Laboratories Limited | novos heterociclos |
KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
CN102596204B (zh) | 2009-07-06 | 2016-11-23 | 波涛生命科学有限公司 | 新的核酸前药及其使用方法 |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
RU2014105311A (ru) | 2011-07-19 | 2015-08-27 | Уэйв Лайф Сайенсес Пте. Лтд. | Способы синтеза функционализованных нуклеиновых кислот |
US9700624B2 (en) | 2012-05-10 | 2017-07-11 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
CN104684893B (zh) | 2012-07-13 | 2016-10-26 | 日本波涛生命科学公司 | 不对称辅助基团 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
EP4137572A1 (en) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
BR112017002629A2 (pt) | 2014-08-15 | 2018-02-20 | Adynxx, Inc. | decoys de oligonucleotídeo para o tratamento de dor |
-
1995
- 1995-05-11 AT AT95919438T patent/ATE271128T1/de active
- 1995-05-11 ES ES95919438T patent/ES2220929T3/es not_active Expired - Lifetime
- 1995-05-11 AU AU25267/95A patent/AU715125B2/en not_active Expired
- 1995-05-11 DK DK95919438T patent/DK0824588T3/da active
- 1995-05-11 MX MX9708663A patent/MX9708663A/es unknown
- 1995-05-11 JP JP53368396A patent/JP4173539B2/ja not_active Expired - Lifetime
- 1995-05-11 WO PCT/EP1995/001778 patent/WO1996035782A1/en active IP Right Grant
- 1995-05-11 RU RU97120584/13A patent/RU2205874C2/ru active
- 1995-05-11 US US08/945,726 patent/US6004813A/en not_active Expired - Lifetime
- 1995-05-11 KR KR1019970708022A patent/KR100449677B1/ko not_active IP Right Cessation
- 1995-05-11 DE DE69533264T patent/DE69533264T2/de not_active Expired - Lifetime
- 1995-05-11 EP EP95919438A patent/EP0824588B1/en not_active Expired - Lifetime
- 1995-05-11 CA CA2220433A patent/CA2220433C/en not_active Expired - Lifetime
- 1995-11-05 UA UA97126018A patent/UA63888C2/uk unknown
-
1996
- 1996-05-06 IL IL11815896A patent/IL118158A/en not_active IP Right Cessation
- 1996-05-07 ZA ZA963593A patent/ZA963593B/xx unknown
-
1998
- 1998-11-09 HK HK98111831A patent/HK1016213A1/xx not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
Gene (abstract) Vol.89(2),p.203-9 (May,1990) * |
Molecular and Cellular Biology. Vol.14(3), p.1657-1668 (Mar,1994) * |
Also Published As
Publication number | Publication date |
---|---|
ZA963593B (en) | 1996-11-25 |
CA2220433C (en) | 2010-02-16 |
ATE271128T1 (de) | 2004-07-15 |
CA2220433A1 (en) | 1996-11-14 |
UA63888C2 (en) | 2004-02-16 |
EP0824588B1 (en) | 2004-07-14 |
WO1996035782A1 (en) | 1996-11-14 |
DK0824588T3 (da) | 2004-08-16 |
HK1016213A1 (en) | 1999-10-29 |
JP4173539B2 (ja) | 2008-10-29 |
EP0824588A1 (en) | 1998-02-25 |
MX9708663A (es) | 1998-02-28 |
RU2205874C2 (ru) | 2003-06-10 |
IL118158A0 (en) | 1996-09-12 |
AU715125B2 (en) | 2000-01-20 |
ES2220929T3 (es) | 2004-12-16 |
AU2526795A (en) | 1996-11-29 |
KR19990014681A (ko) | 1999-02-25 |
DE69533264D1 (de) | 2004-08-19 |
US6004813A (en) | 1999-12-21 |
DE69533264T2 (de) | 2004-11-25 |
JPH11504816A (ja) | 1999-05-11 |
IL118158A (en) | 2004-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100449677B1 (ko) | Il-6 활성 저해 물질 | |
MXPA97008663A (en) | Activity inhibitor i | |
Hattori et al. | Acute-phase reaction induces a specific complex between hepatic nuclear proteins and the interleukin 6 response element of the rat alpha 2-macroglobulin gene. | |
Kadesch et al. | Effects of the position of the simian virus 40 enhancer on expression of multiple transcription units in a single plasmid | |
Ponta et al. | Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties. | |
Speck et al. | Point mutations in the Moloney murine leukemia virus enhancer identify a lymphoid-specific viral core motif and 1, 3-phorbol myristate acetate-inducible element | |
Weinberger et al. | Localization of a repressive sequence contributing to B-cell specificity in the immunoglobulin heavy-chain enhancer | |
Morley et al. | Transcriptional repression of a hormone-responsive promoter | |
Frampton et al. | Synergy between the NF-E1 erythroid-specific transcription factor and the CACCC factor in the erythroid-specific promoter of the human porphobilinogen deaminase gene | |
Ye et al. | Identification of the promoter region of human interleukin 1 type I receptor gene: multiple initiation sites, high G+ C content, and constitutive expression. | |
Ohba et al. | Human sterol carrier protein x/sterol carrier protein 2 gene has two promoters | |
Libermann et al. | Involvement of a second lymphoid-specific enhancer element in the regulation of immunoglobulin heavy-chain gene expression | |
WO1995014775A1 (en) | Translational enhancer dna | |
Yamaguchi et al. | DNA binding site for a factor (s) required to initiate simian virus 40 DNA replication. | |
Katoh et al. | Identification of sequences responsible for positive and negative regulation by E1A in the promoter of H‐2Kbm1 class I MHC gene. | |
McCracken et al. | An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma | |
Grimes et al. | Structural and functional analysis of the rat testis‐specific histone H1t gene | |
Jackson et al. | Transcriptional regulation of the PCNA promoter by p53 | |
Houglum et al. | LAP (NF-IL6) transactivates the collagen alpha 1 (I) gene from a 5'regulatory region. | |
Falzon et al. | Multiple protein-binding sites in an intracisternal A particle long terminal repeat | |
Hadzopoulou-Cladaras et al. | Identification of a cis-acting negative DNA element which modulates human hepatic triglyceride lipase gene expression | |
KR0142675B1 (ko) | 유전자 발현 조절인자 | |
Schuster et al. | Tissue specific trans‐acting factor interaction with proximal rat prolactin gene promoter sequences. | |
Farber et al. | trans-dominant defective mutants of simian virus 40 T antigen | |
Chen et al. | Interleukin-6 responsiveness and cell-specific expression of the rat kininogen gene. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 19971111 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20000307 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20020531 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030529 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20031230 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20040728 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20040911 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20040913 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20070906 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20080911 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20090910 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20100910 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20110729 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20120821 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20120821 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20130819 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20130819 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140826 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20140826 Start annual number: 11 End annual number: 11 |
|
EXPY | Expiration of term | ||
PC1801 | Expiration of term |
Termination date: 20151111 Termination category: Expiration of duration |